Myasthenia gravis: the future is here

• Safety, efficacy, and tolerability of efgartigimod in patients with generalised myasthenia gravis (ADAPT): a multicentre, randomised, placebo-controlled, phase 3 trial

  2021 The Lancet Neurology article Medicine Myasthenia Gravis and Thymoma Open access cited by 7 patents

  733

  citations
• Advances in the understanding of disease mechanisms of autoimmune neuromuscular junction disorders

  2022 The Lancet Neurology article Medicine Myasthenia Gravis and Thymoma Open access

  99

  citations
• Functional monovalency amplifies the pathogenicity of anti-MuSK IgG4 in myasthenia gravis

  2021 Proceedings of the National Academy of Sciences article Medicine Myasthenia Gravis and Thymoma Open access

  55

  citations
• Prevalence and associated factors of fatigue in autoimmune myasthenia gravis

  2021 Neuromuscular Disorders article Medicine Myasthenia Gravis and Thymoma Open access

  34

  citations
• A bioassay for neuromuscular junction-restricted complement activation by myasthenia gravis acetylcholine receptor antibodies

  2022 Journal of Neuroscience Methods article Medicine Myasthenia Gravis and Thymoma Open access

  17

  citations
• MuSK antibodies, lessons learned from poly- and monoclonality

  2020 Journal of Autoimmunity article Medicine Myasthenia Gravis and Thymoma Open access cited by 3 patents

  14

  citations
• Eye Muscle MRI in Myasthenia Gravis and Other Neuromuscular Disorders

  2023 Journal of Neuromuscular Diseases article Medicine Myasthenia Gravis and Thymoma Open access

  9

  citations
• Test–Retest Reliability of Repetitive Ocular Vestibular Evoked Myogenic Potentials in Myasthenia Gravis Patients and Healthy Control Subjects

  2022 Journal of Clinical Neurophysiology article Medicine Myasthenia Gravis and Thymoma Open access

  2

  citations

8 results